Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

Dr. Jason Westin presents in this MEDtalk a trial involving treating patients with relapsed primary or secondary CNS lymphomas with a combination of ibrutinib and nivolumab. Despite limited enrollment due to the COVID-19 pandemic, the study showed a high response rate and some cases of durable, long-term, progression-free survival among the 18 patients enrolled. This suggests the potential benefits of targeted and immune therapies in CNS lymphoma treatment, although further research is needed due to the small sample size.